Star51 Capital

Star51 Capital is an operator-led venture capital firm investing at the convergence of medtech and artificial intelligence. Its technical remit spans artificial intelligence, medtech, digital health, diagnostics, monitoring technologies, the digitalisation of healthcare, and interventional therapies. The firm backs founders and management teams from early through growth stage and typically leads or co-leads the rounds it joins.

The firm's first vehicle, the Star51 Fund, closed with commitments led by Abbott and Mayo Clinic, alongside medtech executives, physicians, and life science professionals. The fund invests across the early-to-growth range rather than at a single entry point. Its opportunity pipeline is drawn from the United States, Europe, and Israel.

Investment decisions are shaped by an explicit contribution test: the firm invests only where its ecosystem can make a meaningful difference to the company. The team is composed of medtech operators who have built, scaled, and exited companies, and it works across clinical, commercial, industry, and operating networks in support of portfolio companies. A stated emphasis is helping those companies pursue clear milestones toward acquisition, with the firm positioning itself as founder- and management-team focused.